Dr. Stinchcomb is involved in numerous research projects focused on the transdermal delivery of drugs to treat a wide range of diseases. Ongoing projects are listed below.




Transdermal delivery of 2-Arachidonoyl glycerol (2-AG) for the treatment of arthritis

R03DA030570 (Stinchcomb PI) 7/1/11-6/30/14 NIH/NIDA

The major goal of this project is to optimize topical delivery of endocannabinoid-like structures.


Quantitative Detection of Cold Flow in Transdermal Systems

U01FD005275 (Hoag and Stinchcomb, Co-PI) 3/1/12-9/1/13 NIPTE-FDA

The goal of this project is to predict cold flow in transdermal systems using NIR spectroscopy.


Microneedle-enhanced codrug delivery for smoking cessation and appetite suppression

21DA31439 (Stinchcomb PI) 07/15/12-04/30/14 NIH/NIDA

The goal of this project is to develop transdermal codrugs of hydroxybupropion and naltrexone.


Transdermal Naltrexone for Opiate Addiction and Alcoholism

R42DA32191 (Stinchcomb PI) 08/01/12-07/30/14 NIH/NIDA

The goal of this project is to develop a microneedle enhanced naltrexone transdermal delivery system.